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Abstract
Background and Objectives: It has become increasingly clear that ATM (ataxia-telangiectasia-mutated) safeguards genome
stability, which is a cornerstone of cellular homeostasis, and ATM IVS 22-77 T.C affects the normal activity of ATM proteins.
However, the association between the ATM IVS 22-77 T.C genetic variant and cancer risk is controversial. Therefore, we
conducted a systematic meta-analysis to estimate the overall cancer risk associated with the polymorphism and to quantify
any potential between-study heterogeneity.
Methods: A total of nine studies including 4,470 cases and 4,862 controls were analyzed for ATM IVS 22-77 T.C association
with cancer risk in this meta-analysis. Heterogeneity among articles and their publication bias were also tested.
Results: Our results showed that no association reached the level of statistical significance in the overall risk. Interestingly, in
the stratified analyses, we observed an inverse relationship in lung and breast cancer.
Conclusion: Further functional research on the ATM mechanism should be performed to explain the inconsistent results in
different cancer types.
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Introduction
Cancer is a multi-factorial disease that results from complex
interactions between environmental and genetic factors [1]. The
genetic factors contribute more to the causation of cancer than do
lifestyle or environmental factors. In terms of genetic factors, the
road to cancer is paved with alterations in the sequence and
organization of the cellular genome that range from single-
nucleotide substitutions to gross chromosomal aberrations [2]. In
recent years, studies based on the candidate-polymorphism
approach markedly increased the number of associations between
polymorphism and cancer risk that could be tested.
Ataxia-telangiectasia (A–T) is a rare autosomal recessive
disorder that affects many parts of the body and has an
exceptionally high incidence of cancer, including breast cancer,
leukemia, and lymphoma [3–5]. A–T is caused by mutations in the
ataxia-telangiectasia- mutated (ATM) gene [6]. The ATM gene is
known to be involved in the cellular response to DNA breaks at
several levels, including cell cycle checkpoint activation, DNA
repair, and induction of apoptosis [7]. The protein encoded by this
gene belongs to the PI3/PI4-kinase family. The human ATM gene
has been mapped to chromosome 11q22–23, and it spans 150 kb
and comprises 66 exons [6].
DNA damage jeopardizes cellular homeostasis and initiates a
response that activates various repair mechanisms that recognize
specific DNA lesions [8]. Double-strand breaks (DSBs) are among
the various types of DNA lesions that are caused by a range of
DNA-damaging agents, such as ionizing radiation and reactive
oxygen, and these DNA lesions are deadly. ATM gene plays a key
role in the recognition, signaling, and repair of DNA DSBs [2,9].
ATM also responds to damage caused during meiosis and mitosis
or by free radicals generated during the metabolism of estrogens or
environmental chemicals. In addition, ATM functions as a
regulator of a wide variety of downstream proteins, including
tumor suppressor P53, BRCA1, oncogenic protein MDM2,
checkpoint kinase CHK2, checkpoint protein RAD50 and DNA
repair protein NBS1 [2,7]. Without these functions, cellular
mitosis is prone to the replication of damaged DNA templates and
the subsequent generation of damaged chromosomes. It is
extremely likely that cancer originates from these altered cells.
ATM safeguards genome stability which is a cornerstone of
cellular homeostasis. After the identification of the ATM gene in
1995 [10], numerous studies have demonstrated that individuals
with ATM have a high incidence of malignancies, particularly
breast cancer [7,11,12].
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may alter the efficiency of cell cycle checkpoint activation, DNA
repair and induction of apoptosis and lead to genetic instability
and increased cancer risk. A single-nucleotide polymorphism
(SNP) IVS 22–77 T.C (rs664677) is located within intron 22 of
the ATM gene and has a minor allele frequency higher than 10%.
In addition, IVS 22–77 T.C is in tight linkage disequilibrium
with IVS48 _ 238 G, another ATM variant allele that was shown
to be an association with breast-cancer risk [13]. To date, many
molecular epidemiological studies have evaluated the role of ATM
IVS 22–77 T.C in cancer development within populations of
different ethnicities [13–21]. However, although some of the case-
control studies have reported an association with the risk of cancer
[13–16,20], other studies have failed to demonstrate any
association [17–19,21]. Inconsistencies among previous studies
might be due to multiple ethnicities, random errors, and moderate
sample sizes. Therefore, the aim of this study was use a meta-
analysis approach to evaluate whether the ATM rs664677
polymorphism is actually associated with disease risk.
Materials and Methods
Eligible studies
For the literature review, we searched the PubMed and Embase
databases (the last search was conducted on May 31, 2011) using
the following search terms: ‘‘ATM’’ and ‘‘cancer’’ or ‘‘tumor’’ and
‘‘polymorphism’’ or ‘‘variant’’. In addition, we screened the
reference lists for all included studies, reviews and meta-analyses.
Validity assessment
Previous studies were included if they contained sufficient
published data regarding the following information: 1) The ATM
rs664677 polymorphism and cancer risk; 2) A human case-control
study of a polymorphism associated with cancer risk; and 3) The
genotype frequencies for both cancer cases and controls. Primary
reasons for the exclusion of studies are listed as follows: 1) the
literature did not contain information regarding cancer research;
2) the study duplicated a previous publication; 3) the study
reported no usable data; and 4) the study only involved a case
population.
Data extraction
The data extracted from each eligible publication included the
following information: the first author’s name, the year published,
the year the data were collected, the country in which the study
was conducted, the ethnicities of the individuals involved, the
cancer type, the source of the controls used, the matching criteria,
the genotyping method, the specimen type, the sample size, the
genotypic frequencies for experimental cases and controls, and the
Hardy-Weinberg equilibrium (HWE) among the controls. Specif-
ically, each selected case was classified as population-based,
hospital-based, or mixed. The ethnicity was classified as Asian or
European. If the ethnicity was not reported, we considered the
ethnicity of the source population of the country where the study
was performed.
Study characteristics
The data from nine cancer case-control publications was used in
these analyses. A summary of the individual studies is given in
Table 1. Because one study presented the data for genotypes as
‘CC and CT/TT’ without presenting data for all three genotypes,
we calculated the odds ratio (OR) for recessive models by statistical
analysis [21].
Statistical analysis
All statistical tests performed in this study were two-tailed and p
values less than 0.05 were considered significant, unless otherwise
stated. Statistical analyses were performed using Stata, version
11.0.
For the control groups of each study, the allelic frequency was
calculated, and the observed genotype frequencies of the rs664677
polymorphism were assessed for Hardy-Weinberg equilibrium
using the test. The publication by Natallia M Akulevich et al. [16]
presented two separate case-control studies. Each study was
considered separately for the pooling analysis. Hence, a total of
nine publications including ten studies were included in the final
meta-analysis. All studies with control groups that were not in
HWE (p,0.05) were excluded.
The strength of the association between the rs664677
polymorphism and cancer risk was evaluated by the odds ratios
(ORs) with 95% confidence intervals (CIs). Pooled estimates of the
ORs and 95% CIs were calculated by logistic regression. The
pooled ORs were calculated for the heterozygote comparison (CT
versus TT), homozygote comparison (CC versus TT), dominant
model (CT/CC versus TT) and recessive model (CC versus CT/
TT), respectively. The values for the ORs and CIs for each
individual were considered twice. The meta-analyses were
stratified by cancer type, ethnicity and source of the controls if
the data permitted; a minimum of three data sources were
required. Of the individual studies included in this pooled analysis,
only one source of controls per study was found in all but two
cases; these studies were combined into the ‘‘mixed’’ group.
The evaluation of the meta-analysis results included an
examination of the heterogeneity, an analysis of the sensitivity,
and an examination for bias. The chi-squared-based Q-statistic
test was used to assess the between-study heterogeneity, and it was
considered significant if P,0.10. The fixed and random effects
models were performed, respectively, to combine values from each
of the studies based on the Mantel-Haenszel [22] and the
DerSimonian and Laird [23]methods. When the effects were
assumed to be homogenous, the fixed-effects model was used;
otherwise, it was more appropriate to use the random-effects
model. The sensitivity analyses were performed to assess
robustness and examine the results of our meta-analyses for
possible biases.
The inverted funnel plots and Egger’s regression test were used
to investigate the publication bias. The potential publication bias
was assessed with funnel plots of the effect sizes versus the standard
errors; the Begg’s test was used to identify the significant
asymmetry. An asymmetric plot suggests possible publication bias.
The bias due to results from small studies was evaluated by the
modified Egger’s test, which corrected for potential type I errors
[24].
Results
Flow of included studies
A total of 110 publications were relevant to the search words.
Seven studies were obviously irrelevant. Forty studies were
excluded because they were duplicates of previous publications
(27 studies) or on different genes (13 articles). Four of the articles
were meta-analyses, and six of the publications were reviews.
Among the remaining 53 publications, six of the articles were not
human studies, five of the publications were not for cancer
research and six articles had no control population. Another
twenty-eight studies were also excluded because they did not
present detailed genotyping information (19 articles) or did not
report usable data (9 articles). Finally, the references from all
ATM Polymorphism and Cancer Risk: A Meta-Analysis
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additional eligible article was retrieved. Overall, nine studies,
involving 4,470 cases and 4,862 controls, concerning ATM
rs664677 polymorphism and cancer susceptibility were available
for this meta-analysis (Figure 1).
Characteristics of studies
The studies investigating different cancers, multiple ethnicity or
different sources of controls were separated into multiple studies in
a subgroup analysis. In addition, one study [21] that only provided
the total number of common genotypes (TT and CT) was included
in the analysis for the recessive model but not for other genetic
models. For the ATM rs664677 polymorphism, there were four
studies of Asian descendents and five studies of European
descendents. Finally, our meta-analysis consisted of nine case-
control studies: three breast cancer studies, four lung cancer
studies, one papillary thyroid carcinoma study, and one pancreatic
cancer study; in most cases, the cancers were diagnosed
histologically or pathologically. In addition, five studies were
population-based and two studies were hospital-based; the two
publications that did not provide detailed information regarding
the source of the controls were mixed. The genotype distributions
in the controls for all studies were consistent with Hardy-Weinberg
equilibrium, except for a part of one study [16] (Table 1).
Quantitative synthesis
It is known that the frequency of the ATM rs664677
polymorphism varies between ethnic groups. For the European
populations (n=1542), the cc allele frequency was 40.9% (95%
CI=33.4–48.4), which was significantly lower than that of the
Asian population (n=2780, 60.6%, 95% CI=57.5–63.8;
Figure 2).
The individual risk estimates (Table 2) were calculated and
presented as forest plots (Figure 3a) by study type for all nine
studies included in the analysis. Overall, no significant association
between the ATM rs664677 polymorphism and cancer risk was
observed in any genetic model (heterozygote comparison:
OR=1.018, 95% CI=0.791–1.311; dominant model compari-
son: OR=1.026, 95% CI=0.812–1.295). Again, the cancer cases
and controls did not significantly differ in the subgroup analyses
according to the ethnicity and the source of controls. Intriguingly,
the ATM rs664677 polymorphism showed evidence of an
association with an increased risk for breast cancer (dominant
model comparison: OR=1.447, 95% CI=1.203–1.740), but
demonstrated a protective role in the development of lung cancer
in the meta-analyses stratified by cancer type (dominant model
comparison: OR=0.764, 95% CI=0.635–0.918; Figure 3b).
Test for heterogeneity
There was significant heterogeneity in the homozygote (CC
versus TT: P heterogeneity=0.003), heterozygote (CT versus TT:
P heterogeneity,0.001), and dominant model (AA/GA versus
GG: P heterogeneity,0.001) comparisons. However, in the
recessive model comparison (CC versus CT/TT: P heterogene-
ity=0.539), heterogeneity was not found. We evaluated the source
of heterogeneity by tumor type, ethnicity, publication year, control
source, and sample size. We did not observe any contribution to
the substantial heterogeneity.
Sensitivity analyses
Sensitivity analyses were conducted to ascertain the primary
origin of the heterogeneity. Four independent studies by Sang-Ah
Lee [15], Stefano Landi [18], Kyoung-Mu Lee [20], and Sandra
Angele [13] affected the heterogeneity. The heterogeneity was
Table 1. Overview of the 9 studies included in the pooled reanalysis with individual data.
First author Year
year of data
collection Country Ethnicity Cancer type
Source of
controls
Matching
criteria
Genotyping
method Cases/controls HWE
Lo [14] 2010 2002.1–2006.12 China Asian Lung PCC age, gender,
and smoking
status
MassARRAY 730/730 0.41
Lee [15] 2010 2001–2003 Korea Asian Breast HCC age PCR, TaqMan 206/253 0.49
Akulevich
(a)
[16]
2009 — Japan European Papillary thyroid
carcinoma
PCC age, IR-exposed
status
PCR-RFLP 88/133 0.31
Akulevich
(b)
[16]
2009 — Japan European Papillary thyroid
carcinoma
PCC age,
Non-exposed
PCR-RFLP 87/398 0.00*
Li [17] 2009 2000–2007 USA European Pancreatic Cancer PCC age,sex, race. TaqMan 734/780 0.44
Yang [21] 2007 1995–2007 USA European Lung PCC Age, gender,
ethnicity and
smoking status
TaqMan 547/540 0.34
Landi [18] 2006 1998.2–2002.10 Romania,
Hungary,
Poland,Russia,
Slovakia,Czech
Republic
European Lung MIXED random PCR,
microarray
299/317 0.05
Kim [19] 2006 2001–2003 Korea Asian Lung HCC Age, sex,family
history of cancer
PCR,
SNPstream
616/616 0.06
Lee [20] 2005 1995–2003 Korea Asian Breast MIXED reproductive/
parity factors
PCR, TaqMan 996/1181 0.17
Angele [13] 2003 1996.2–2002.4 France European Breast PCC age PCR-RFLP 254/312 0.87
HCC, hospital-based case–control; PCC, population-based case–control; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; HWE, Hardy-
Weinberg equilibrium.
*Controls in Hardy–Weinberg equilibrium: P,0.05.
doi:10.1371/journal.pone.0029479.t001
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studies (CC/CT versus TT: P heterogeneity=0.601). Further-
more, no single study changed the pooled ORs qualitatively,
suggesting that the results of this meta-analysis were stable.
Publication bias
Begger’s funnel plot and Egger’s test were used to identify the
potential publication biases of the literature, the shapes of the
funnel plots appeared to be symmetrical (Figure 3), suggesting that
there was no obvious publication bias. Egger’s test was used to
provide further statistical evidence; similarly, the results showed no
significant publication bias in this meta-analysis (t=20.02,
P=0.984 for cc vs. tt)
Discussion
In response to DNA damage, the dormant kinase and sensors of
ATM are rapidly activated, and various downstream substrates of
ATM, which compose an ever-expanding network, are phosphor-
ylated. Some of the downstream substrates are key factors in the
regulation of cell-cycle arrest, DNA repair, and apoptosis. Given
the important roles of ATM in response to DNA damage,
inherited variability in this gene could directly or indirectly
contribute to susceptibility to cancer [12].
Several studies have reported the associations between several
genetic variants of ATM and risk of cancer, for instance,
rs1800057 (P1054R), rs1801516 (D1853N) and rs1800054
(S49C) [25–28]. Some of these SNPs involved in the nonsynon-
ymous variants which caused the amino acid alteration and might
have a physiologic effect on cancer development. Here, we focused
on the association between a synonymous SNP (rs664677) and
cancer risk. ATM IVS 22–77 T.C (rs664677) is located in the
noncoding region. One of the possible mechanisms for IVS 22–77
T.C in the ATM gene seemed to be mediated by affecting RNA
splicing [29]. The other possible mechanism might be the
influences of mRNA stability. However, the actual mechanism
of IVS 22–77 T.C in the ATM gene remains uncertain.
The present meta-analysis of 9 studies, including 4470 cases and
4862 controls, provided evidence that there is no association
between cancer and the ATM rs664677 polymorphism. The
results from a recent meta-analysis investigation of the association
between the ATM D1853N polymorphism and breast cancer risk
presented evidence consistent with our results [30]. Moreover, in
subgroup studies by source of controls and ethnicity, no significant
associations were found in any genetic models. However, the
rs664677 polymorphism in the Asian and European populations
was observed to have an inverse association with cancer risk in all
genetic models, although without any significance. Considering
that the ATM polymorphism presents with different frequencies in
different populations, analysis of the data respectively from the
various ethnic groups might eliminate some bias. And this
discrepancy we observed may be due to the difference in the
source of the controls. The source of controls of the initial studies
might have a weak effect on the results in our analysis. However,
we thought the population-based controls were more representa-
tive of the general population. Thus, in genetic association studies,
the selection of controls and matching status should be carefully
considered. If we use the population-based controls, we can obtain
a higher reliability.
In the subgroup analysis according to cancer type, the odds
ratio for CC homozygosity versus heterozygosity plus TT
homozygosity was decreased for lung cancer, but this was not
statistically significant (0.972; 95% CI=0.851–1.111). In other
models, however, the OR was significantly decreased. In contrast
to lung cancer, where the ATM rs664677 C allele is protective, in
breast cancer, it seems to be associated with an elevated risk. Such
Figure 1. Studies identified with criteria for inclusion and exclusion.
doi:10.1371/journal.pone.0029479.g001
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doi:10.1371/journal.pone.0029479.g002
Table 2. Results of the pooled data analyses for the 9 studied and subgroup analysis for ATM rs664677 and cancer risk.
Variables n
a Case/Controls CC Versus TT CT Vs TT CC/CT Vs TT(dominant) CC Vs CT/TT (recessive)
OR(95% CI) P
c OR(95% CI) P
c OR(95% CI) P
c OR(95% CI) P
c
Total 8/(9)
b 3923/4322,
(4470/4862)
b
1.018(0.791–1.311)
d 0.003 1.023(0.809–1.292)
d 0 1.026(0.812–1.295)
d 0 1.014(0.924–1.113) 0.593
Cancer types
Lung Cancer 3/(4)
b 1645/1663,
(2192/2203)
b
0.797(0.644–0.986) 0.725 0.756(0.623–0.917) 0.443 0.764(0.635–0.918) 0.448 0.972(0.851–1.111) 0.942
Breast Cancer 3 1456/1746 1.507(1.213–1.872) 0.652 1.422(1.171–1.727) 0.697 1.448(1.204–1.741) 0.696 1.137(0.976–1.324) 0.575
Other cancers 2 822/913 0.808(0.609–1.073) 0.658 0.898(0.730–1.104) 0.104 0.877(0.721–1.068) 0.21 0.865(0.672–1.115) 0.215
Ethnicities
Asian 4 2548/2780 1.119(0.780–1.604)
d 0.007 1.103(0.772–1.574)
d 0.005 1.113(0.778–1.591)
d 0.003 1.033(0.924–1.156) 0.631
European 4/(5)
b 1375/1542,
(1922/2082)
b
0.909(0.618–1.338)
d 0.058 0.953(0.679–1.338)
d 0.01 0.949(0.679–1.327)
d 0.007 0.974(0.825–1.150) 0.293
Source of controls
Population-based 4/(5)
b 1806/1955,
(2353/2495)
b
0.927(0.670–1.281)
d 0.075 0.994(0.764–1.292)
d 0.055 0.989(0.756–1.293)
d 0.048 0.963(0.839–1.106) 0.287
Hospital-based 2 822/869 1.225(0.594–2.526)
d 0.036 1.182(0.567–2.463)
d 0.029 1.025(0.580–2.504)
d 0.019 1.051(0.863–1.281) 0.493
Mixed 2 1295/1498 1.012(0.5–2.048)
d 0.01 0.943(0.424–2.094)
d 0 0.955(0.439–2.076)
d 0.001 1.065(0.904–1.255) 0.459
aNumber of comparisons;
brecessive model differ from other models in these respects;
cP value of Q-test for heterogeneity test;
dRandom-effects model was used when P value for heterogeneity test,0.10; otherwise, fix-effects model was used.
doi:10.1371/journal.pone.0029479.t002
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CHEK2 I157T variant with the rare allele conferred an elevated
breast cancer risk but a protective effect on lung cancer [31].
Interestingly, we observed the association exhibit a disaccord in
breast and lung cancer risks, which could be caused by the
following two reasons: one might be that non-genetic factors are
likely to have entirely different mechanisms that affect tumorigen-
esis in concert with genotype. For instance, gene-environment
interactions might modulate cancer risk. The other possible reason
is that ATM utilizes diversity mechanisms that regulate cell
proliferation or apoptosis in different cancer cells.
Recent genome-wide association studies (GWAS) have reported
several SNP to be associated with breast or lung cancer, including
rs1219648, rs1092913, rs2736100, rs16969968, rs8034191, and
rs402710 et al [32–41]. While no GWAS data reported the
association of rs664677 with breast or lung cancer to date. As we
known, in GWAS, four key points (models of the allelic
architecture of common diseases, sample size, map density and
sample-collection biases) need to be taken into account in order to
optimize the cost efficiency of identifying genuine disease-
susceptibility loci [42]. Due to the strict criteria, some low-risk
alleles might be overlooked in spite of their potential importance in
disease risk.
A literature reviewed that eight hallmarks constitute an
organizing principle for rationalizing the complexities of neoplastic
disease. They include sustaining proliferative signaling, evading
growth suppressors, resisting cell death, enabling replicative
immortality, inducing angiogenesis, activating invasion and
metastasis, reprogramming energy metabolism and evading
immune destruction [43]. Studies with ataxia telangiectasia (A–
T) cells and ATM-deficient mice have shown that ATM is a key
regulator of the multiple signaling cascades that respond to DNA
strand breaks induced by damaging agents or by normal processes,
such as meiotic or V(D)J recombination. These responses involve
the activation of cell cycle checkpoints, DNA repair and apoptosis
[7]. Considering the ATM multifunction, it might affect several
pathways in the hallmarks and therefore involve diverse
mechanisms in different cancer types. To date, the pathway
through which the ATM polymorphism acts is unclear. Further
research is necessary.
Heterogeneity is a potential problem that might affect the
interpretation of the results. Significance between the meta-
analysis heterogeneity existed in almost all comparisons, except the
recessive model. We detected the source of heterogeneity by tumor
type, ethnicity, publication year, control source, and sample size.
However, there was no evidence to determine which of them
contributed to the substantial heterogeneity. One possibility
involves differences in the matching status. However, we cannot
confirm this possibility because no detailed information was
provided. Heterogeneity could also have resulted from the fact that
each study used a different approach to select participants.
However, it seems unlikely that the selection procedure would
affect the genotype at the locus. Thus, we do not have a clear
explanation for the statistical heterogeneity that was present for
the SNP. The leave-one-out sensitivity analysis would not have
materially altered the results of this pooled analysis, indicating that
our results were robust. The publication bias for the association
between this polymorphism and cancer risk was not observed.
Limitations
Several potential limitations of the present meta-analysis should
be taken into consideration. First, although the funnel plot and
Egger’s test showed no publication bias and although an
exhaustive literature search was done, it is likely that some
publications and unpublished data were overlooked. Selection bias
for the meta-analysis might have occurred. Secondly, in the
subgroup analysis by cancer type, the number of studies and
subjects analyzed for rs664677 was small, and the statistical power
was so low that caution should be taken in interpreting these
results. A further investigation with much larger sample sizes is
needed. Thirdly, our results were based on unadjusted estimates
due to the absence of available information. A more precise
analysis would be detected if more detailed individual data were
available, such as age, sex, and exposure. Despite its limitations,
our meta-analysis also had some advantages. There was no
evidence for heterogeneity in a recessive model among the studies
Figure 3. Funnel plot analysis to detect publication bias. Each point represents a separate study for the indicated association (CC
VS CT/TT).
doi:10.1371/journal.pone.0029479.g003
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polymorphism contributing to both cancer suppressing and
promoting effects.
In summary, this meta-analysis convincingly demonstrated that
the ATM rs664677 polymorphism is not associated with cancer
risk. A moderately protective effect was observed with the lung
cancer risk. In contrast, we observed an elevated risk of breast
cancer susceptibility. In conclusion, well-designed, unbiased
studies should be done to gain a more comprehensive under-
standing of the association between the ATM gene and cancer
risk.
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